NBDF/LinkedIn
Sep 11, 2025, 13:37
Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial
National Bleeding Disorders Foundation shared on LinkedIn:
”Promising news for the hemophilia community!
Pfizer’s HYMPAVZI™ (marstacimab-hncq) shows a 93% reduction in treated bleeds in its Phase 3 trial for people with hemophilia A or B with inhibitors.”
Learn more here.
Stay updated on the emerging in the field of hemophilia with Hemostasis Today.
-
Oct 27, 2025, 12:12Maria Roussakis: It is an Honour to Be a Part of the ISBT Young Professionals Council
-
Oct 27, 2025, 05:47Ahmed Koriesh on The Novel Approach in Use of Tenecteplase
-
Oct 27, 2025, 04:42Louise Breslin: Exciting Results in The CRYPTICS Trial
-
Oct 26, 2025, 16:55ECTH 2025: 3 Unforgettable Days of Science and Shared Purpose
-
Oct 26, 2025, 16:35Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 27, 2025, 05:00Wolfgang Miesbach on WFH Guidelines Covering FDA/EMA-Approved AAV Gene Therapy for Hemophilia
-
Oct 26, 2025, 15:04Nita Radhakrishnan and Colleagues on Inherited Haematological Conditions
-
Oct 26, 2025, 14:55Anirban Sen Gupta on Biosynthetic Blood Surrogates Current State-of-Art
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
-
Oct 27, 2025, 06:30Andres Ricaurte Fajardo on CVT Experience from a Latin American Cohort
Oct 27, 2025, 13:18
Oct 27, 2025, 13:00
Oct 27, 2025, 12:54
Oct 27, 2025, 08:01
Oct 27, 2025, 08:00
Oct 27, 2025, 06:30
Oct 27, 2025, 05:47
Oct 27, 2025, 05:15
Oct 27, 2025, 04:42